(TheNewswire)
Calgary, Alberta, Canada – TheNewswire - March 13, 2024 - Voyageur PharmaceuticalsLtd . ( TSX.V: VM ) (USA: VYYRF) ("Voyageur"or the "Corporation"), announces a significant advancementin its partnership with Rain Cage Carbon Inc. ("Rain Cage").This milestone signifies the execution of a royalty agreement thatsolidifies the exclusive development and license agreement between theparties and it further reinforces Voyageur’s commitment topioneering sustainable carbon drug development.
Brent Willis, CEO of Voyageur states, “Voyageur ispioneering the development of the world's first carbon-neutralpharmaceutical company. Our groundbreaking carbon drug program mayrevolutionize the industry, by harnessing captured CO 2 as its primary ingredient. Thisinnovative approach not only aligns with sustainable practices butalso positions Voyageur as a trailblazer in the radiology drug marketthrough seamless vertical integration. Our Rain Cage partnership isshaping the future of environmentally conscious and cutting-edgepharmaceutical solutions.”
Driving Innovation in HealthcareImaging
Voyageur and Rain Cage have solidified their strategicalliance and are poised to redefine healthcare imaging technologies.The execution of the royalty agreement underscores their shareddedication to leveraging Rain Cage's pioneering EDEN™ carbon capturetechnology for the creation of innovative nanocarbon/fullerene-basedimaging drugs.
Building an Eco-Friendly DrugPipeline
In alignment with its sustainable goals, Voyageur isforging ahead with the establishment of an eco-friendly drug pipeline.This pipeline includes barium sulfate contrast media, iodinatedcontrast media, and carbon contrast media products, forming anintegral part of Voyageur's Earth to Bottle strategic businessplan.
Pioneering MRI DrugDevelopment
With a focus on innovation, Voyageur is spearheadingthe development of a new MRI drug utilising the V@C60 molecule( https://voyageurpharmaceuticals.ca/voyageur-pharmaceuticals-ltd-and-rain-cage-carbon-inc-announce-breakthrough-in-imaging-technology-with-vanadium-fullerene-molecule/ ). This breakthrough holds promisefor revolutionizing MRI imaging as well as facilitating targeted drugdelivery of contrast agents to specific areas of the body.
Sustainable Carbon Production forFuture Growth
Building upon Rain Cage’s breakthrough in carbonproduction from captured CO 2 , Voyageur is poised for sustainable growth ( https://sustainablebiz.ca/rain-cage-carbon-produce-carbon-based-fullerenes-scale ). The preparation of a carbon production Revenue SharingAgreement is underway to exploit carbon captured and leverage the cashflow generated by carbon production technologyat Voyageur's future pharmaceutical manufacturing facility. Voyageuris evaluating several existing pharmaceutical facilities, to enablethe vertical integration of its pharmaceutical projects and align withits vision of integrating sustainability into pharmaceuticalproduction.
Leading the Way in PharmaceuticalSustainability
Voyageur's partnership with Rain Cage underscores itsleadership in sustainable pharmaceutical development. By executing theroyalty agreement and advancing eco-friendly drug development,Voyageur is contributing to a healthier future and a greener planet.
About Voyageur PharmaceuticalsLtd.
Voyageur, a Canadian public company trading under thesymbol VM on the TSXV, is in development of barium and iodine ActivePharmaceutical Ingredients (API) and high-performance, cost-effectiveimaging contrast agents. With a strategic focus on verticallyintegrating the barium and iodine contrast market, Voyageur aims tobecome a key player by producing its own barium, iodine, and fullereneminerals.
Voyageur's business plan is set to generate immediatecash flow by partnering with established third-party GMPpharmaceutical manufacturers in Canada, ensuring the validation of itsproducts by regulatory agencies worldwide. As Voyageur solidifies itspresence in the market, it will transition into a high-margin domesticmanufacturer of radiology drugs, further expanding its revenuestreams.
Voyageur is committed to sustainability andenvironmental stewardship. Voyageur envisions a future where carbonneutrality is the norm, and to achieve this, it is buildingstate-of-the-art carbon-neutral infrastructure. By investing in carbonneutral energy sources and sustainable manufacturing practices,Voyageur aims to become 100% self-sufficient across all of itsmanufacturing activities. Voyageur's unwavering commitment to theenvironment sets it apart as a pioneer in the industry.
At the core of its operations, Voyageur owns a 100%interest in the Frances Creek barium sulphate (barite) project. Thisproject boasts exceptional grade minerals suitable for thepharmaceutical marketplace.
Voyageur's ambitious vision is to become the firstvertically integrated, carbon-neutral company in the radiologycontrast media drug market. By controlling all primary input costs,from the sourcing of raw materials to the final production, Voyageurensures unmatched quality and cost efficiency. With its revolutionary approach, it embodies the motto of " From the Earth to the Bottle ," highlighting Voyageur's commitment to responsiblesourcing and manufacturing practices.
About Rain Cage Carbon Inc.
Rain Cage is a pioneering private Canadian companydedicated to decarbonizing industries by capturing CO 2 and other emissions and transformingthem into engineered carbon. Through its proprietary technology,EDEN™, it offers companies a groundbreaking solution to combatcarbon pollution. Rain Cage's unique approach not only helps mitigateemissions but also harnesses contaminating energy and converts it intoa recyclable technology with countless applications.
For Further Information:
Brent Willis, CEO, | Albert Deslauriers, CFO, |
Brent@vpharma.ca | Albert@vpharma.ca |
info@vpharma.ca | https://voyageurpharmaceuticals.ca/ |
Neither the TSX Venture Exchange nor its Regulation ServicesProvider (as that term is defined in the policies of the TSX VentureExchange) accepts responsibility for the adequacy or accuracy of thisnews release.
Cautionary Statement Regarding “Forward-Looking”Information
This news release may containcertain forward-looking information and statements, including withoutlimitation, statements pertaining to: the success of utilizing RainCage's EDEN TM carbon capture technology to create innovativenanocarbon/fullerene-based imaging drugs and the success of theCorporation's profitability manufacturing and distributing thosedrugs; all required regulatory approvals being obtained for themanufacture and sale of the nanocarbon/fullerene-based imaging drugs;the market for fullerene based contrast agents; the EDEN TM technology being carbon neutral; andavailability of financing. All statements included herein, other thanstatements of historical fact, are forward-looking information andsuch information involves various risks and uncertainties. There canbe no assurance that such information will prove to be accurate, andactual results and future events could differ materially from thoseanticipated in such information. A description of assumptions used todevelop such forward-looking information and a description of riskfactors that may cause actual results to differ materially fromforward-looking information can be found in the Company's disclosuredocuments on the SEDAR+ website at www.sedarplus.ca. Voyageur does notundertake to update any forward-looking information except in accordance with applicable securitieslaws.
Copyright (c) 2024 TheNewswire - All rights reserved.